In a new study by University of Manchester scientists published in , researchers aimed to uncover why these treatments fail for some individuals. To do this, the team analysed blood samples from people living with MG and compared them to those of healthy volunteers to understand the underlying cellular differences that drive standard therapy resistance.

A Pattern of Immune Imbalance
The study revealed distinct immune system abnormalities in patients with refractory MG. These patients showed an overactive adaptive immune response, specifically involving increased numbers of memory B cells.

At the same time, the researchers found that regulatory T cells—which normally act as a ‘braking system’ to suppress excessive inflammation—were markedly reduced. This combination of an overactive attack and a weakened braking system contributes to significant immune dysregulation.

The research also identified changes in the innate immune system, including reduced dendritic cells and increased monocytes, along with heightened activity of the complement system, all pointing to ongoing immune-mediated damage at the neuromuscular junction.

Predicting Treatment Response
The team also examined a small group of refractory patients treated with rituximab, a drug designed to remove B cells. Although B cells were successfully reduced in all patients, only some showed meaningful clinical improvement.

The study found that those who did not respond appeared to have a version of the disease driven by long-lived plasma cells and particularly high complement activity. This discovery suggests that these specific patients may benefit more from therapies that target the complement pathway rather than just B cells.

“For patients whose symptoms do not improve with existing treatments, the lack of clear answers can be incredibly frustrating,” said , Neurology Consultant at 91ֱ�� Centre for Clinical Neuroscience. “Our findings help explain why some therapies work for certain patients but not others, and point toward more personalised approaches that could improve outcomes in the future.”

“Our study identifies a distinct immune signature associated with treatment-resistant myasthenia gravis,” said , UKRI Future Leaders Fellow at the  and lead author of the paper. “Understanding these immune differences brings us closer to predicting how patients will respond to therapy and to developing more targeted, personalised treatment approaches.”

• Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis published in . DOI: 

The second half goes here

Published in the journal European Urology Oncology today (20/02/26), the researchers show men with learning disabilities are 35% more likely than similar aged men without learning disabilities to have prostate cancer symptoms but 34% less likely to have a diagnostic PSA (Prostate-Specific Antigen) test. 

The study is funded by the National Institute for Health and Care Research (NIHR) Greater 91ֱ�� Patient Safety Research Collaboration (GM PSRC). The research team is supported by both the NIHR GM PSRC and the NIHR 91ֱ�� Biomedical Research Centre (BRC). 

Following an elevated PSA, referrals are 17% less likely, biopsies 46% less likely and prostate cancer diagnoses 49% less likely. 

They were almost six times more likely to be diagnosed with prostate cancer on the date of death, 79% more likely to present with metastatic disease at an advanced stage and had a two-fold increased risk of death following diagnosis. 

And they were also 61% more likely to have missing Gleason scores, the grading system used to evaluate prostate cancer based on how cancer cells look under a microscope. 

However, when prostate cancer was diagnosed at a localised stage and deemed to require treatment, men with learning disabilities received curative therapies at similar rates to those without. This suggests that the benefits of early diagnosis apply equally to this group.

The study population comprised 29,554 men with a learning disability compared to 518,739 men with no recorded diagnosis of a learning disability, linked to hospital, mortality, and cancer registry data. 

Lead author Dr Oliver Kennedy a clinical lecturer from The University of Manchester and The Christie NHS Foundation Trust said: “Learning disabilities are increasingly recognised as a hidden driver of cancer mortality. However, evidence on prostate cancer care in this population is limited. 

“This study is the first to identify specific points along the prostate cancer diagnostic and treatment pathway that may contribute to poorer outcomes for patients with a learning disability.” 

And co-author , director of the NIHR Greater 91ֱ�� PSRC and professor at The University of Manchester, said: “Learning – or intellectual - disability is a lifelong neurodevelopmental condition characterised by significant impairments in intellectual functioning and adaptive behaviour, with onset in childhood. 

“In the UK, 1.5 million people have a learning disability. This group frequently encounters barriers within healthcare services, including communication difficulties, not doing enough to remove barriers, and the overshadowing of new symptoms on existing  health conditions. 

“Men with a learning disability face disparities across the prostate cancer care pathway, from investigation of relevant symptoms to survival after diagnosis. Targeted interventions are needed to address these inequities.”

Dr Kennedy added: “Addressing these health disparities has been recognised as a priority by the NHS Long Term Plan, National Institute for Health and Care Excellence guidance, and the Learning from Lives and Deaths programme in England.

“We hope our study provides strong evidence that prostate cancer should be part of that conversation

Jon Sparkes OBE, Chief Executive of learning disability charity Mencap, said: “Too many men with a learning disability are being let down by a health system that doesn’t spot their cancers early enough or support them to navigate complex treatments.

“This important research into what is now the most commonly diagnosed cancer in the UK should be a wake-up call: with the right reasonable adjustments, accessible information and specialist support, these inequalities are not inevitable.

“T����dzܲ��� we’re working with health partners across the UK to get more people on the Learning Disability Register. Being on the register means they’ll receive free annual health checks and support in the way they need it, so health problems can be spotted and treated earlier.

“But we can’t do this alone. We need the NHS, government and cancer services to join us in making inclusive health a priority – acting on this evidence and putting the right support in place at every stage of the cancer pathway.”

Natalia Norori, Head of Data & Evidence at Prostate Cancer UK, said: "The results of this paper are deeply concerning. It sheds light on the stark inequalities men with learning disabilities face at every stage of the pathway - from diagnosis, to treatment and even death.

"This issue goes beyond prostate cancer, but by understanding the impact of these inequalities in the most common cancer in the UK, we can begin to tackle it.

"More work now needs to be done to understand more about why these men are facing so many obstacles to accessing care and how to prevent them. That's why Prostate Cancer UK's TRANSFORM screening trial has been specifically designed to evaluate the impact of screening in all men, including those with learning disabilities, to ensure no man is left behind."

• The paper Prostate Cancer Care in Men with an Intellectual Disability: A Population-Based Cohort 91ֱ�� of Symptoms, Diagnosis, Treatment and Survival is  available DOI : https://doi.org/10.1016/j.euo.2026.01.004

From the 23rd to the 27th February 2026, a new exhibition will showcase the exciting work of ' and its' digital research activity.

Focusing on its five research themes - Digital Cultures, Digital Economy, Digital Health, Digital Society and Digital Worlds, and two capability themes - Digital Skills and AI@91ֱ��, the exhibition will present a series of posters and the existing multidisciplinary strengths at The University of Manchester.

The exhibition will be at based in space B2 on the Ground Floor of The Nancy Rothwell Building all week. Visit us to learn more and explore new ways to shape our digital future!

The landmark licensing agreement was announced at a celebration of the sixtieth anniversary of the Cypriot university this week (18 Feb) in Limassol.

The University of Manchester’s School of Medical Sciences programme will be used as a model to develop a new offering to teach undergraduate medical students at a new medical school in 2028, with a new building planned at the Limassol campus.

The agreement is testament to the quality of medical education at 91ֱ�� which can trace its roots way back over 250 years.

It is also reflects the university’s commitment to  social responsibility by helping to reduce the global deficit of health professionals.

The University of Manchester will provide training to support staff at Frederick University working with two private hospitals in Limassol: Ygia hospital and the Mediterranean Hospital of Cyprus to deliver clinical placements for the Frederick University medical students.

The programme is being thoughtfully adapted to reflect the healthcare priorities, regulatory framework, and cultural context of Cyprus, ensuring that graduates are prepared to meet local and regional medical needs while benefiting from an internationally respected academic framework.

The programme, which is still being finalised, will be submitted to the Cyprus Agency of Quality Assurance and Accreditation in Higher Education.

91ֱ��, one of the UK’s leading centres for medical education, research, and clinical excellence, will provide ongoing support and training for each academic year.

Deputy Dean and Deputy Vice President of the Faculty of Biology, Medicine and Health at The University of Manchester, Professor Allan Pacey and Professor Margaret Kingston,  Director of Undergraduate Medical and Dental Studies, were at the celebration.

Professor Pacey said: “As one of the United Kingdom’s largest and most innovative medical schools, we are delighted to announce this partnership.

“Based in one of Europe’s largest healthcare hubs in 91ֱ��, our medical students benefit from early patient contact, world-class teaching hospitals, and a curriculum grounded in innovation, compassion, and evidence-based practice.

“Graduates leave not only as highly skilled clinicians, but as leaders ready to shape the future of global healthcare.

“We are delighted to be able to share our experience with Frederick University so they will be able to nurture their own world class medics in Cyprus.”

Professor Tony Heagerty, Head of the School of Medical Sciences said: “The University of Manchester,  founded as a civic university, has had a historic focus on social responsibility and this partnership has been built on a foundation of those shared values.  

“Our agreement between School of Medical Sciences and Frederick University  reflects our part in helping to reduce the global deficit of health professionals.

“And It aligns with the university's commitment to ensuring teaching can make a positive, ethical, and lasting impact on society.

“In Frederick, we recognise a partner which is also focused on making a difference in Cyprus and the rest of the world.”

President of the Council of Frederick University, Natassa Frederickou said: “We are honoured to partner with The University of Manchester in this landmark collaboration, which marks an important milestone for Frederick University and for the development of medical education in Cyprus.

“The establishment of the first Medical School in Limassol reflects the shared long-term vision of Frederick University and The University of Manchester to advance medical education and research in the region. This partnership is grounded in a common commitment to academic excellence, social responsibility, and global impact.

“By sharing the curriculum approach, academic philosophy, and rigorous standards associated with one of the world’s leading medical schools, we will offer education of international calibre. Together, we aim to educate future doctors who combine scientific expertise with compassion, while strengthening healthcare systems and advancing medical research for the benefit of society. This partnership is built on shared values, and we are proud to take this significant step forward together.”

The briefing – drawing on research and insights from academics at The University of Manchester– finds that healthcare in prisons is fragmented across the health and justice departments, with responsibility split between multiple agencies and service providers and no single body in charge. Poor coordination between the Department of Health and Social Care, the Ministry of Justice and healthcare providers continues to undermine the quality and continuity of care available to prisoners.

This lack of joined-up working is compounded by severe pressures in the prison system itself. Overcrowding, staff shortages and an ageing, crumbling prison estate are making it harder to deliver basic healthcare and are contributing to poor health outcomes among prisoners. On average, people in prison have a life expectancy more than 20 years lower than the general population. While around 70% of prisoners are estimated to need mental health support, only around 10% are recorded as receiving treatment.[1]

Supporting people’s underlying health needs has been identified as a critical component of reducing reoffending. Chief Medical Officer for England, Professor Chris Whitty, highlighted offending and reoffending are strongly linked to health, with the greatest risks occur at moments of transition: entry into prison, transfers between facilities, and after release.[2]

The pressures within the system are only set to get worse, due to an ageing prison population. Nearly 1 in 4 prisoners is now aged 50 or over, a group with complex and chronic health needs that prisons were never designed to meet.[3] Deaths from natural causes among older prisoners have increased over the past decades, yet access to appropriate care, including palliative and end-of-life support, remains inconsistent.

The SMF warns that without reform, the prison health system will continue to miss the chance to break cycles of ill health, disadvantage and crime.

To address these challenges, the Social Market Foundation sets out four key priorities for government, including:

• establishing a sustainable, long-term funding settlement for prison healthcare;
• improving coordination and integration between health services, justice agencies and service providers;
• prioritising prevention and early intervention; and
• strengthening cross-government oversight of prisoner health.

Jake Shepherd, Senior Researcher at the Social Market Foundation, said: "Healthcare is a human right – that includes people in prison. Many prisoners enter custody in poor health, and weaknesses in the system mean health outcomes in prison are consistently worse than in the wider population. While investing in prison health may not be politically popular, it brings wider public health benefits and can help reduce reoffending, leading to long-term savings. Prison health is therefore not just a moral issue, but a practical one”.

“The Government should start by investing more, focusing on prevention, and improving how organisations work together on prisoner healthcare, to make prisons safer places that support healthy lives and rehabilitation.”

, Senior Research Fellow in Social Care and Society at The University of Manchester said: “This report from Policy@91ֱ�� and the Social Market Foundation identifies the systemic barriers that prevent people living in prison from accessing the health and social care they need. Health and social care in prisons should be on an equivalent footing to services provided in the community, but research at The University of Manchester shows this is consistently not the case. 

“Poor health amongst people living in prison is the product of overstretched systems, deteriorating environments, and long‑standing inequalities that follow people into prison. Crucially, this work highlights the growing health needs of older people and women of all ages living in prison. Addressing these issues will deliver benefits far beyond the prison walls, and policymakers should act on the evidence-led recommendations this report provides.” 

• The SMF report will be published at   

[1] Mental Health in Prison.

[2] The Health of People in Prison, on Probation, and in the Secure NHS Estate in England (Department of Health and Social Care and Ministry of Justice, 2025).

[3] ^cx The Health of People in Prison, on Probation, and in the Secure NHS Estate in England.

Earth-observation satellites are increasingly relied upon to support efforts to meet the United Nations’ 17 Sustainable Development Goals (SDGs), providing critical data on issues like land use, urban development, ecosystems and disaster response. However, the rapid growth of satellite missions is also making Earth’s orbits more crowded and hazardous, increasing the risk of collisions and the creation of long-lasting space debris.

There are currently around 11,800 active satellites in orbit, but some predictions suggest that number could rise to more than 100,000 by the end of the decade. Collisions in space can generate large amounts of debris, threatening satellites, astronauts and the long-term usability of key orbital regions.

The new model, which links satellite mission objectives with collision risk as a key first step in mission design, is presented in the journal .

Lead author , PhD researcher at The University of Manchester, said: “Our research addresses what is described as a “space sustainability paradox”, the risk that using satellites to solve environmental and social challenges on Earth could ultimately undermine the long-term sustainability of space itself.

“By integrating collision risk into early mission design, we ensure Earth-observation missions can be planned more responsibly, balancing data quality with the need to protect the orbital environment.”

Many applications that support the SDGs rely on very high-resolution satellite imagery. To achieve this level of detail, satellites often operate at lower altitudes, which reduces their field of view. Alternatively, they can operate at higher altitudes but must be larger and heavier to carry bigger optical systems. This increases their exposure to space debris and makes collisions more likely and potentially more damaging.

The new modelling framework allows satellite performance requirements and collision risk to be considered together during mission design, rather than being assessed separately or late in development.

The approach links mission requirements, such as image resolution and coverage, with estimates of satellite size, mass, the numbers of satellites in a constellation, and the level of debris present in different regions of low Earth orbit. This allows designers to explore how different mission choices affect both data quality and collision risk.

Using the model, the researchers found that collision risk does not simply peak where debris is most concentrated - satellite size also plays a major role. For example, for a satellite designed to deliver 0.5 metre resolution imagery, collision probability was highest between 850 and 950 kilometres above Earth - about 50 kilometres higher than the peak in debris density.

The study also found that although higher orbits require fewer satellites to achieve coverage, those satellites carry a greater individual collision risk because they are much larger. Lower orbits need more satellites, but each one can be smaller and therefore less hazardous.

Dr , Lecturer in Aerospace Systems at The University of Manchester, said: “As satellite use continues to grow, our method offers a practical way to ensure that space remains safe, sustainable and usable for generations to come, while still delivering the data needed to address the world’s most pressing challenges.”

, Professor of Space Technology at The University of Manchester, added: “The method could also be adapted for different Earth-observation systems and expanded to include more detailed space-environment impacts. In future work, we could account for how long debris fragments stay in orbit, how likely they are to hit other satellites, and the wider environmental effects of satellite re-entry. This would allow mission designers to evaluate trade-offs across the full sustainability picture.”

This research was published in the journal Advances in Space Research

Full title: Collision risk from performance requirements in Earth observation mission design

DOI:

“Faster access to emergency funding, more resilient supply chains and better disaster planning could help prevent payment delays from turning into job losses and business failures.” 

DOI:

The test, say the researchers, could identify individuals at risk of the condition which is typified by loss of muscle mass and strength as well as an overall poorer quality of life. 

The study, published in the journal PLOS Med today (12/02/26) and  funded by Kidney Research UK and the Donal O'Donoghue Renal Research Centre”, is the first large scale study to demonstrate the viability of the test -  called  creatinine muscle index (CMI) in CKD. 

The researchers created CMI by combining two routine blood tests, creatinine and cystatin C. 

While both tests used to assess kidney function, creatinine levels are influenced by how much muscle a person has, whereas cystatin C is not. 

By comparing the two, the researchers were able to use this difference to estimate a person’s risk of muscle loss and therefore sarcopenia. 

Because kidney disease affects how creatinine is processed, scientists did not know if CMI would work well in people with CKD. 

However, the study shows that CMI remains independently associated with both muscle function and survival. 

The test could enable earlier detection of sarcopenia, allowing patients to start proven interventions—such as resistance exercise training and protein supplementation—sooner, and potentially lower their risk of death.

The study included 2,930 adults with non-dialysis CKD from 16 kidney centres across the UK  between July 2017 and September 2019.

Participants had their CMI and muscle function in terms of grip strength and walking speed measured and were followed up for a median of 50 months.

In both men and women, lower CMI  - indicating lower muscle mass-   was linked to weaker hand grip strength, slower walking speed and a higher risk of sarcopenia.

Higher CMI was also linked to a lower risk of death. The average CMI in men and women was 864 mg/day and 704 mg/day. For every 100 mg/day per 1.73 m² increase in CMI The risk of death fell by 15% in men and 23% in women.

And CMI outperformed other cystatin C–creatinine–based measures in predicting mortality and sarcopenia.

Lead author Dr is both a researcher at The University of Manchester and a kidney doctor at Salford Royal Hospital, part of Northern Care Alliance NHS Foundation Trust.

He said: “Sarcopenia, in people with chronic kidney disease is  associated with increased mortality, poorer self-reported health-related quality of life, and reduced functional status.

“Simple identification of sarcopenia should be routinely undertaken in people with CKD, not only because of its association with adverse outcomes but also due to the availability of interventions that can reverse it in people with CKD.

“That could have significant implications on patient wellbeing.

“Our findings also highlight CMI’s superiority over alternative tests, and provides exciting evidence for  its potential as a blood-based biomarker of sarcopenia and mortality risk.”

NURTuRE-CKD is a prospective, multicentre cohort study of people with non-dialysis CKD in the U.K

The paper Associations of Creatinine Muscle Index with Markers of Sarcopenia and Mortality in 1 Chronic Kidney Disease: A Prospective Cohort 91ֱ�� is available

The global list recognises individuals whose work is transforming the future of medicine and public health.

Professor Bigger, now based at The University of Edinburgh, is internationally regarded for pioneering a novel gene therapy for Hunter syndrome, a rare and potentially life‑threatening inherited condition that affects young children.

The disease causes a progressive, dementia‑like decline alongside severe deterioration of organ systems, placing immense emotional and physical strain on families.

For decades, congenital genetic diseases like Hunter syndrome have faced limited treatment options.

Because they affect relatively small numbers of children, they have historically received less attention from drug developers, leaving families with few therapeutic avenues and little hope for long‑term improvement. However, Professor Bigger’s research helped shift the  landscape.

His work focuses on delivering a missing gene—responsible for producing a critical enzyme—into patients' own blood stem cells, which engraft in the bone marrow and brain. The enzyme is also tagged with a peptide to improve uptake into the brain where it is needed, a challenge that has long hindered progress in treating neurodegenerative childhood disorders.

The therapy aims not only to slow the disease but to fundamentally alter its trajectory.

In February 2025, a boy from California became the first patient in the world to receive infusions of the gene therapy developed in Bigger’s laboratory as part of an early‑stage clinical study.

Now three years old, he has shown sustained improvement, offering new optimism for families affected by the condition and marking a milestone in the field of paediatric gene therapy.

Professor Bigger said: “It came as a tremendous surprise and honour to receive this recognition from TIME. I am humbled to be included in such an esteemed group of innovators and leaders, who are impacting and advancing the world of health.

“This recognition really belongs to the hard work of so many colleagues in 91ֱ�� and Edinburgh, as well as collaborators, patient organisations and families, scientists and clinicians, academia and industry, working together to make our stem cell gene therapies for childhood dementia a reality.

“I hope this recognition will mean that we can help more families with these devastating diseases through innovative stem cell and gene therapies for dementia and beyond.”

DOI:

DOI:  

The discovery, published in the journal eLife today (insert date), sheds light on how animals integrate sensory information to guide reproduction and has, say the researchers, general implications on understanding the brains’ role in reproduction. 

When male fruit flies mate, they transfer a molecule called sex peptide (SP) to the female. 

This molecule triggers two key changes: females reject courting males who want to mate again, and they lay more eggs. 

Although scientists have known about SP for years, until now the precise neurons in the female nervous system that respond have remained a mystery. 

The  findings suggest that the brain allows females to fine‑tune their responses to mating depending on their internal state and environmental conditions — helping them maximise the chances of reproductive success. 

Lead author, Dr Mohanakarthik Nallasivan, from the University of Birmingham said: “Reproductive behaviours are hardwired in the brain, rather than learned. So if we can understand this behavioural pathway, we may be able to influence it. 

“Knowing the exact nerve cells that drive key behavioural changes in female fruit flies after they mate is a very important step along that path. 

“This knowledge could, for example,  help develop methods to restrict the ability of malaria carrying female Anopheles mosquitoes to mate, which precedes the blood-meal.”

91ֱ��-lead from The University of Manchester added: “The fruit fly was the first organism with a fully sequenced genome. Now, in 2022, it is the first brain to have all its neurons catalogued and synaptic connections mapped”.

“We now have the resources available to learn how behaviour is encoded in the brain and influenced by decision making processes”.

“This pioneering work has implications for increasing our understanding of how our own brains work, particularly those behaviours that are ‘hard wired’, or built into our neural circuitry.”

To identify the neurons, the research team attached the sex peptide pheromone, that normally circulates in the insects’ blood after mating, to the cell-membrane on the outside of neurons.

When such membrane-tethered sex-peptide is expressed in the same nerve cell as its receptor, post-mating behaviours will be triggered.

To understand how the brain responds to the sex peptide, the scientists explored the complex genetic framework of key reproductive genes involved in sex determination, resulting in male or female offspring.

By combining genetic tools that mark a handful of neurons controlled by reproductive genes, the scientists identified two distinct sets of interneurons — one in the brain and one in the abdominal nerve centre — that regulate the behaviours.

The approach allowed them to pinpoint the neurons that detect the sex peptide, which they named Sex Peptide Response‑Inducing Neurons (SPRINz).

Further mapping of the neural circuits showed that SPRINz receive signals from sensory‑processing neurons and send outputs along two separate pathways.

Artificially activating SPRINz in the brain induced post‑mating behaviours, effectively mimicking a command. This demonstrates that sex‑peptide‑responsive neurons act as central hubs, integrating sensory cues and coordinating the female’s behavioural decisions after mating.

• A draft of the paper, Sex-peptide targets distinct higher order processing neurons in the brain to induce the female post-mating response  is available

Professor Boya placed as a finalist due to her world-leading work in a sub-field of advanced materials called nanocapillaries. This field is focused on atomically thin channels (capillaries) in which water and gas behave in surprising ways, flowing faster and separating differently. Her discoveries offer new models for brain signalling and enable advances in brain-inspired computing and molecular filtration.

Now in their ninth year in the UK, the 2026 Blavatnik Awards for Young Scientists received 91 nominations from 46 academic and research institutions across England, Northern Ireland, Scotland and Wales. A distinguished jury of leading senior scientists and engineers from throughout the UK selects the Laureates and finalists.

Despite their young age, Blavatnik scholars are driving global economic growth by pursuing high-risk, high-reward research. To date, Blavatnik Awards honourees have founded over 50 companies after receiving the award, six of which are publicly traded and collectively valued at over $10 billion.

Internationally recognised by the scientific community, the Blavatnik Awards for Young Scientists are instrumental in expanding engagement and recognition for young scientists and in providing the support and encouragement needed to drive scientific innovation for the next generation.

The Blavatnik Awards in the UK sit alongside their global counterparts, the and the in the United States, and the , all of which honour and support exceptional early-career scientists. By the close of 2026, the Blavatnik Awards will have awarded prizes totalling over $20 million to over 500 scientists and engineers worldwide.

“The Awards were created to honour outstanding, early-career scientists, accelerate their research, and ensure that discoveries with the potential to dramatically improve society are recognized, supported, and implemented,” said , Founder of Access Industries and the Blavatnik Family Foundation.

Members of the public interested in learning more about this year’s honourees' research may register to attend a free public symposium titled “Leading with Discovery: UK Scientists Shaping Global Science” at the Royal Society of Medicine on Wednesday, 25 February 2026, from 10:00 to 15:00 GMT. To attend this FREE public symposium, register .

To find out more about the awards, Laureates and finalists, please visit the 

Lauren Caulfield, a student at the University of Manchester, was named winner of the Outstanding Contribution to Pregnancy Loss and Bereavement Care category at the RCM Awards ceremony in London on Friday 6 February.

Lauren decided to become a midwife after the heartbreaking loss of her daughter and has since become a passionate advocate for improving how families are supported after pregnancy loss.

Her lived experience led her to co-design a digital bereavement clinical placement, created to help student midwives learn even when they may not encounter bereavement care during placements. The programme uses guidance, real parent stories and scenario-based learning to help students develop the language, confidence and sensitivity needed to care for bereaved families.

Since it launched, it has already supported more than 100 students and is now being evaluated during a pilot across multiple universities.

The judges praised Lauren’s clear message that bereavement care should be part of every midwife’s training, not treated as a separate specialty. She has worked closely with parents and charities including the baby loss charity Sands to make sure education reflects what families really need, and has helped create practical, accessible learning tools to build confidence for students and staff.

Gill Walton, Chief Executive of the RCM, said: “Lauren has taken a deeply personal experience and turned it into practical change that will help families across the UK. Her work is thoughtful, compassionate and focused on giving student midwives and staff the confidence to provide sensitive, consistent bereavement care. She is a hugely deserving winner.”

Speaking at the event after winning her award, Lauren said: “It’s really amazing to be recognised for the work I’ve been doing. I just really hope all the work I’m doing supports all the families across the country to make sure there is amazing and consistent bereavement care for every family.”

Margaret Walsh, Lead Midwife for Education and Dr Helen White, Senior Lecturer in Midwifery at the University of Manchester, said: “Congratulations to Lauren on winning this prestigious award. We are proud that Lauren has been recognised for her strong commitment to improving the support and care of women who have experienced pregnancy loss. Lauren has dedicated both her passion and commitment to improving bereavement care, using her creativity and innovation to find ways to support those who care for bereaved women and families.”

The RCM Awards are held annually and honour outstanding individuals in maternity care who have made a positive impact on women, babies and their families, showcasing world-class midwifery standards.

• image shows Lauren, second left, with awards host Suzi Ruffell, RCM Scotland director Jaki Lambert, RCM president Sophie Russell and RCM Chief Executive Gill Walton.

The research, conducted by , placed 91ֱ�� first followed by Birmingham, Nottingham, Warwick and University College London. 91ֱ�� formerly placed second in the rankings in the report’s 2025 edition. 

91ֱ�� has reclaimed the top spot, reaffirming its position as the most highly targeted university by the UK’s leading graduate employers in an increasingly competitive market. 

The Graduate Market is an annual review of the graduate job market, with this year’s report based on research completed in December 2025 with 100 of the UK’s leading graduate employers.  

Researchers identified the top five institutions which attract the most top graduate employers to university careers fairs, on-campus employers’ presentations, careers service promotions and other locally-run publicity throughout 2025-2026.  

On average, the number of universities targeted by employers averaged around 23 in the latest academic year. This ranking demonstrates how 91ֱ�� graduates remain a priority target for employers in the face of a challenging graduate job market. 

The top 100 employers reduced graduate hiring again in 2025 (–5.1%) and are forecasting a further slight dip in 2026 (–0.5%), bringing vacancies to their lowest level since 2012.

The University of Manchester places consistently in the top 100 of world universities across a number of rankings, most recently placing ninth in the QS World University Rankings: Europe 2026. In the QS Rankings for Employability, The University of Manchester ranks fourth for Employment Outcomes and third place for Employer Reputation in the Russell Group.

91ֱ�� was also recognised among the top 100 globally across 10 subject areas in the Times Higher Education (THE) World University Rankings 2026 by Subject. 

Other rankings for The University of Manchester are available here. 

As large language models such as ChatGPT and Gemini have rapidly improved in recent years, many widely used benchmarks have become less informative. In 2023, leading models were found to pass the and, separately, in 2025, achieved gold medal-level performance on , achieving over 80% accuracy.

Now, two 91ֱ�� mathematicians, Dr Cesare Giulio Ardito and Dr Igor Chernyavsky, have joined nearly 1,000 expert contributors worldwide to create a multidisciplinary academic test called “” (HLE), which sets AI systems a fresh challenge.

The test consists of 2,500 rigorously reviewed questions spanning dozens of disciplines, from mathematics and the natural sciences to humanities. Questions are deliberately precise, closed-ended and resistant to simple internet search or memorisation, with some using both textual and image data.

Every question in HLE was tested against leading AI models before inclusion. If an AI system could answer a question correctly at the time the benchmark was designed, it was rejected.

The study, now published in , found they passed fewer than 10% of the HLE questions when the dataset was first released in early 2025, despite scoring above 80% on more conventional benchmarks.

Although the rapid pace of AI development has enabled some systems to significantly improve their scores in less than a year, the top-ranked models still reach just below 40%. The results also show that many AI systems still frequently express high confidence in incorrect answers to the HLE questions. However, their capability in self-assessing knowledge gaps has gradually improved.

said: “I'm happy that the University of Manchester is represented among contributors from all over the world. This was a human team effort and, so far, we appear to still have an edge.”

Although this new AI benchmark only measures performance on closed-ended, expert-level questions at the frontier of current knowledge, the authors hope it will help identify remaining limitations and potentially capture emerging generalist research capabilities.

This research was published in the journal Nature

Full title: A benchmark of expert-level academic questions to assess AI capabilities

DOI:  

This research by The University of Manchester and 91ֱ�� University NHS Foundation Trust (MFT) scientists is the first of its kind to show people who stop using a prescribed treatment for COPD are at significantly higher risk of exacerbations than expected for their disease.

COPD is the name for a group of lung conditions that cause breathing difficulties, including emphysema and chronic bronchitis. COPD is a common condition, affecting about 1 in 20 people aged over 40 in England, and is a major cause of death and disability.

People with COPD often experience ‘exacerbations’ – sudden flare-ups of breathlessness and coughing that make their condition much worse. These exacerbations are a leading cause of emergency hospital admissions.

Treatment for COPD can help slow the progression of the condition, control symptoms and prevent flare-ups. This includes taking inhalers which deliver medicine into the lungs to help make breathing easier.

91ֱ�� lead Dr Alexander , researcher in the NIHR 91ֱ�� BRC’s Respiratory Theme and a Senior Clinical Lecturer at The University of Manchester, said: “Many people with COPD use inhalers every day, but some only use them for a short time and then stop. They may feel better and think they no longer need them, they may struggle to afford them if they are not free of charge, or they may simply forget to use them. Overall, that around half of all prescribed doses are missed.”

In this new study, 91ֱ�� researchers analysed data from the 2013-2016 FLAME trial, a large international research project sponsored by Novartis which investigated how patients respond to different COPD treatments. Novartis shared these trial data as per standard data sharing practices with the independent research team in 91ֱ�� to answer additional research questions beyond the original study.

The FLAME trial compared 2 types of in more than 3,300 participants with COPD – these are effective treatments used to open up the airways and reduce inflammation in COPD.

The team found that when people with COPD stop their inhalers, they face a significantly increased risk of flare-ups for around 3 months. Importantly, during this period the risk is higher not only compared with their own usual level of risk, but also compared with people who were not taking these medicines at all.

The study followed patients for a full year after stopping treatment and showed that this increase in risk is temporary. The excess risk of flare-ups is concentrated in the first 3 months after stopping inhalers, over and above what would normally be expected following treatment discontinuation. After this period, the risk settles and does not persist beyond 3 months.

The study, published in , showed for the first time that stopping a common type of inhaler called a LAMA (long-acting muscarinic antagonist) can lead to these withdrawal effects. It also confirmed that stopping inhalers containing another medication called inhaled corticosteroids (ICS) can increase the risk of flare-ups.

Dr Mathioudakis, who is also an Honorary Consultant Respiratory Physician at MFT and completed his PhD in COPD research at 91ֱ�� BRC, said: “There are situations where clinicians may need to change or stop an inhaler for specific medical reasons, and in these cases it is important to be aware that short-term “withdrawal effects” can occur.

“More importantly, many people with COPD stop their inhalers on their own, often repeatedly, without medical advice. Each time this happens, it can trigger a period of particularly high risk of exacerbations. These new findings highlight the need to clearly communicate the risks of stopping treatment to patients, to help prevent avoidable flare-ups and hospital admissions.”

• The paper “Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial” is available : DOI:

The agenda included a stakeholder meeting at Christie’s Bistro on The University of 91ֱ��’s campus on Wednesday 4 February, and a creative roundtable in MediaCity on Thursday 5 February, hosted by Professor of Poetry, John McAuliffe, on the role of the creative economy in innovation. 

Transport for Greater 91ֱ�� (TfGM) also hosted a meeting to showcase 91ֱ��’s transport network, providing the chance to share learnings between the two cities, before the first partnership advisory board meeting was held at the Graphene Engineering Innovation Centre (GEIC). 

The events were attended by both the mayors of Greater 91ֱ�� and Cambridgeshire and Peterborough respectively, Andy Burnham and Paul Bristow, and the Vice-Chancellors of the Universities of Manchester and Cambridge, Professor Duncan Ivison and Professor Deborah Prentice. Attendees also included the leaders of both city councils, Shaun Grady, UK Chair of AstraZeneca, and industry leaders from both regions.  

The visit to 91ֱ�� follows on from the launch of the partnership and the initial stakeholder visit to Cambridge last year, after £4.8 million in funding was awarded by Research England for the pioneering city-to-city collaboration.  

In October, the partnership announced its advisory board during the 2025 Innovate Cambridge Summit which brings together leaders from academia, industry and policy to guide the collaboration between the two cities. 

The partnership is led by the universities of Cambridge and 91ֱ�� and their innovation ecosystem organisations  and . The ambitious collaboration was launched to boost UK economic growth and advance inclusive innovation, while supporting the delivery of industrial strategy and local growth plans. 

The partnership is connected at every level: University to University, innovation ecosystem to ecosystem, council to council, Combined Authority to Combined Authority and business to business. This multi-layered connectivity allows ideas, talent, investment and opportunity to flow between places and organisations.   

Find out more about the partnership and get involved –   

The Research England funding has been allocated for use in three key areas: ecosystem activation and integration; growing investment; and testing and learning. 

● Ecosystem activation and integration: It will strengthen relations within and between the innovation ecosystems of the two cities, to create a vibrant and ambitious cross-city innovation network. This aims to create progressive new approach inclusive growth. 

● Growing investment: It will harness the combined strengths of both universities and partner cities to support start-ups and scale-ups to secure funding and grow, attract innovation-intensive FDI to the UK, and stimulate investment into R&D. 

● Testing and learning: It will pilot new approaches and share best practice for delivering ecosystem collaboration and inclusive growth. This will allow other cities, the wider higher education sector community, and local and national governments in the UK and internationally to learn from the partnership. 

Building on the success of the 2024 CBI Mayoral Roundtable, the summit focused on a singular mission: turning regional potential into tangible economic results. During a roundtable attendees agreed on a framework to unlock long-term private investment and enhance the UK’s regional competitiveness.

Duncan Ivison, President & Vice-Chancellor of The University of Manchester, said: “We are delighted to host this summit on our campus, bringing together leaders from business, government and civil society in 91ֱ��. Delivering an effective industrial strategy must be underpinned by robust academic evidence, and The University of Manchester has an important role to play in that work.

“Here in Greater 91ֱ��, we are part of a close partnership between business, policymakers and communities, and are pleased to be a helpful convenor, and contributor, to discussions and collaborations that support the UK’s future."

The summit identified three critical pillars for accelerated implementation of the Industrial Strategy with the potential to deliver transformative gains to regional growth that boost jobs, opportunities and living standards across England:

·&�Բ�����;&�Բ�����;&�Բ�����;&�Բ�����;&�Բ�����;&�Բ�����; Investable Pipelines: Creating clear, ready-to-fund projects that attract global capital.

·&�Բ�����;&�Բ�����;&�Բ�����;&�Բ�����;&�Բ�����;&�Բ�����; Deepened Partnerships: Strengthening the "front door" for businesses through closer Mayoral collaboration.

·&�Բ�����;&�Բ�����;&�Բ�����;&�Բ�����;&�Բ�����;&�Բ�����; Innovation Engines: Leveraging the power of higher education to fuel local talent and R&D.

The afternoon concluded with reflections from Rain Newton-Smith (CBI), Charlie Nunn (Lloyds Banking Group), and Andy Burnham (Mayor of Greater 91ֱ��), highlighting the essential role of regional leadership in the UK’s economic future.

Rain Newton-Smith, CBI CEO, said: “The government has set out bold ambitions for the UK to lead the G7 in driving business investment into the UK. PWC’s recent survey of global CEOs places the UK as the second most attractive location alongside Germany and India so there is no doubt the appetite is there. Building on and championing the unique capabilities of all of our regions is essential if we’re to secure that investment and turn those bold ambitions into tangible economic growth that benefits the whole country.

“Metro mayors are our regional ambassadors in chief, and provide a single, locally-responsive, front door for that investment – helping to remove potential barriers and expedite decision-making. With the power to boost local skills delivery, accelerate critical planning and infrastructure decisions, and smooth access to market opportunities, mayors play a vital role in ensuring investment comes to the UK and is not lost to our global competitors.”

Charlie Nunn, Chief Executive, Lloyds Banking Group said: “Businesses are the engines of regional growth, innovation and job creation, and we want to help them succeed.  This year, we’re making available £35 billion in new finance for businesses across the regions, with one third targeted to SMEs.  We’re proud to be working in partnership across regional leaders, higher education and major infrastructure, in order to attract investment and catalyse growth.”

This event is a cornerstone of the CBI-Lloyds Industrial Strategy Roadshow, a 12-month delivery programme in partnership with DBT and HMT to help government and industry work together to deliver a successful industrial strategy.

Researchers at The University of Manchester's have now achieved the first atomic‑resolution imaging of monolayer transition metal diiodides, made possible by creating graphene‑sealed TEM samples that prevent these highly reactive materials from degrading on contact with air. The study, published in , demonstrates that fully encapsulating the crystals in graphene preserves atomically clean interfaces and extends their usable lifetime from seconds to months. This capability arises from refinements to an inorganic stamp transfer approach the team previously developed and reported in , which provided the basis for producing stable, hermetically sealed samples.

“Working with these materials felt impossible at first as they are completely destroyed after a few seconds air exposure, preventing traditional fabrication approaches.” explained Dr Wendong Wang who has worked on developing the transfer technique and fabricated the samples in question. “Our approach protects samples r without any unnecessary transfer stages. Being able to make samples that can survive not just hours but months, and for international transfer between facilities, solves a major bottleneck in 2D materials research.“

“Once we were able to make stable samples, we were able to make several interesting observations about these materials, including identifying extensive local structural variations for the thinnest samples, atomic defect dynamics and edge structure evolution”, states Dr Gareth Tainton who conducted the TEM imaging and analysis as part of this work. “The structures of 2D materials are closely linked to their properties, and so being able to directly observe not only the structures of the different crystals, from monolayers up to bulk thicknesses, but also defect behaviour will hopefully inform further work on these materials to unlock their potential in technology”

“What excites me most is how this opens up previously inaccessible scientific territory. We've known theoretically that many reactive 2D materials have exceptional properties for electronics, optoelectronics, and quantum applications, but we couldn't get stable samples into the lab to test those predictions", commented Prof Roman Gorbachev of the National Graphene Institute, who led the investigation. 

This research was published in the journal ACS Nano.

Full title: Atomic Imaging of 2D Transition Metal Diiodides

DOI:

Professor Roman Gorbachev is available for interview on request.

The study, led by the University of Aberdeen in collaboration with colleagues from the University of Manchester, University College Cork and University of Birmingham, was funded by Tommy’s, the pregnancy and baby charity, and published in .

Led by Dr Andrea Woolner, Senior Clinical Lecturer at the University of Aberdeen and Honorary Consultant Obstetrician & Early Pregnancy Lead at NHS Grampian, the team looked at survey responses from 116 healthcare professionals working in maternity services in the UK and Ireland.

Second trimester pregnancy loss (STPL) usually refers to pregnancy loss, or miscarriage after 12 or 13 weeks' gestation. It is estimated to occur in around 3 to 4% of pregnancies. However, this study showed the definition used to describe STPL in healthcare settings varies considerably within the UK and Ireland.

Findings revealed that there is inconsistency and uncertainty around medications used following second trimester pregnancy loss (STPL), which the authors state reflects the lack of research into this devastating type of loss.

For example, almost two thirds of healthcare professionals surveyed (63%) acknowledged they were uncertain about the optimal dosage of misoprostol - a drug that can be given following STPL to induce birth - that should be used, likely due to a lack of research in this area, according to the authors.

Researchers also found that care was given in different hospital wards and not always within maternity settings in different parts of the UK and Ireland.  The authors say this highlights the need to consider how hospitals are set up for couples experiencing STPL, and to consider what the optimal referral pathways and infrastructure needs are.  The team intends to carry out further research exploring views of those with lived experience of STPL.

Following treatment in hospital, fewer than half (45%) of respondents reported that follow-up appointments took place in a dedicated pregnancy loss clinic. Many women were offered follow up in preterm birth clinics, though the research team notes this wasn’t always universal either as not every STPL involves a preterm labour.

There is a growing body of evidence that shows structured care in a dedicated pregnancy loss clinic is the best option for couples who have experienced a stillbirth (when a baby sadly dies after 24 weeks of pregnancy), and researchers say the findings of the study underline the inconsistencies faced by families who lose a baby at different stages of pregnancy.

They also noted there was variation in the investigations and care offered in the next pregnancy after a second trimester loss.

Researchers say more work is needed to understand what the best treatments are and what universal provisions should be made for couples facing the devastation of second trimester pregnancy loss

The team is planning to gain insight from those with lived experience, with the aim of developing a clear view of what is needed to improve care for the future and understanding what research is needed urgently to address these gaps.

Dr Andrea Woolner said: “Pregnancy loss at any stage is devastating. This study showed that there is a lack of research and evidence–based clinical practice around STPL in particular.

“In this survey, we wanted to hear from the people on the ground who work with bereaved parents, to find out exactly where the disparities lie from a healthcare professional perspective and what we need to do to improve things.

“Our findings highlight the lack of standardised care – this is important because we know that pregnancy loss at any stage of pregnancy has a profound impact on couples and on their next pregnancies.

“Ensuring that evidence-based and universal recommendations for birth, bereavement and future antenatal care are offered to all couples after pregnancy loss is vital, and akin to the recommendations for care after stillbirth, we hope that this work highlights clinicians, policy-makers and researchers need to also focus on care for second trimester pregnancy loss.

Professor Alex Heazell, one of the co-authors from the University of Manchester and Director of Tommy’s Maternal and Fetal Health Research Centre in 91ֱ��, said: “ which showed fragmented and inconsistent care provisions but also highlighted the number of women who present to hospital in the second trimester with various symptoms including those that may be a sign of pregnancy loss.

“We urgently need better quality data to help us provide the best care.”

Dr Jyotsna Vohra, Director of Research, Programmes and Impact at Tommy’s, said: “Losing a baby is devastating at any stage of pregnancy. When the loss happens after 12 weeks – the stage at which people are often encouraged to believe they are ‘safe’ – it can be particularly traumatic for women and families.

“This study shows we need more research and better standardised care across the NHS so that anyone experiencing symptoms of loss at any stage of pregnancy knows they will receive the most effective care, treatment and support.”

The study, led by The University of Manchester, suggests that while removing livestock from upland grasslands can increase fast-cycling carbon stored in plants and dead vegetation, it can also lead to losses of a more stable form of soil carbon. This long-lived carbon, known as mineral-associated organic carbon (MAOC), is bound to soil minerals and can persist for decades to centuries, making it critical for long-term climate mitigation.

Grasslands store around one-third of the world’s terrestrial carbon, with the vast majority being found in soils. As governments pursue net-zero targets, removing livestock from historically grazed grasslands has increasingly been proposed as a scalable climate solution.

Traditionally, scientists and land managers have relied on “total carbon stocks” to assess carbon removal projects. However, the new findings, published in the today, show that focusing solely on the total amount of carbon stored, rather than how securely it is stored, may be misleading.

“While ungrazed grasslands tend to accumulate more unprotected carbon in plants and litter, they are associated with lower levels of soil carbon protected by minerals, which is the form most resistant to warming-induced decomposition,” explained Dr Luhong Zhou, lead author of the study and visiting scholar at The University of Manchester. “Although high grazing intensity can negatively affect soil carbon, our results show that total grazer exclusion does not necessarily lead to greater long-term soil carbon storage.”

The team of researchers from The University of Manchester (UK), Lancaster University (UK), Yale University (USA), Fujian Normal University (China), and Leiden University (the Netherlands), analysed 12 upland grassland sites across an 800-kilometre south–north gradient in the United Kingdom, from Dartmoor to Glensaugh in Scotland. At each site, they compared grasslands that had been ungrazed for more than ten years with neighbouring areas that had been grazed over that time.

They found that ungrazed grasslands tended to accumulate more short-lived carbon in plant biomass and surface litter but generally contained lower levels of MAOC.

The decline in long-lived soil carbon is linked to changes in vegetation following the removal of grazing sheep. As a result, grass-dominated landscapes are increasingly replaced by dwarf shrubs such as heather. The roots of the shrubs form associations with a specialised fungi called ericoid mycorrhiza. These fungi slow the decay of plant litter, causing an increase in production of short-lived carbon but also stimulating the breakdown of older, more stable soil carbon, in order to gain nutrients to sustain plant growth. Wetter soils can also further weaken the minerals that normally help protect MAOC.

“Viewing grazer removal as a universally beneficial strategy for carbon mitigation often overlooks the continuum of carbon durability within ecosystems, and the fact that not all carbon gains contribute equally to long-term climate mitigation,” said Dr Shangshi Liu from the Yale Center for Natural Carbon Capture who co-led this study. “ When slow-cycling carbon declines, grassland carbon stocks may become more vulnerable to future climate change. Effective climate mitigation strategies must therefore consider  both how much carbon is stored and how durable it is”

The findings come at a critical time for environmental management policy in the UK and globally, as governments develop land-use frameworks to meet net-zero targets.  

Professor Richard Bardgett, Chair of Ecology at Lancaster University, who initiated the study while at The University of Manchester, said: “Our results suggest that maintaining low-intensity grazing in upland grasslands, which cover large areas in the United Kingdom, is important for protecting the most stable forms of soil carbon.”

The authors emphasise that their findings do not argue against reducing overgrazing. Rather, they call for more balanced grassland management approaches that account for both total carbon stocks and carbon persistence.

The study was funded by the UK Natural Environment Research Council (NERC), the Biotechnology and Biological Sciences Research Council (BBSRC), the European Research Council (ERC), and Yale Center for Natural Carbon Capture fellowship.

The findings are Published in PNAS

Full title: Grazer exclusion is associated with higher fast-cycling carbon pools but lower slow-cycling mineral-associated carbon across grasslands

DOI:

“At a time when many people feel overwhelmed or anxious about the future, these experiences often helped people reconnect with hope and a sense of purpose.”

“This research shows that therapy doesn’t always have to happen in a room,” said co-author Professor Terry Hanley. “For some people, being outdoors creates the space they need to reflect, heal and move forward. As mental health services face growing demand, nature-based approaches could be a valuable part of a wider, more humane response to wellbeing.”

DOI:

Developed through the Greater 91ֱ�� Civic University Agreement, the initiative enables postgraduate researchers to teach up to 20 hours per week in FE settings, providing specialist expertise in priority subjects such as engineering, STEM and digital skills. In turn, the programme offers researchers valuable, paid teaching experience while helping colleges tackle critical local and regional skills gaps.

University of Manchester President and Vice-Chancellor Professor Duncan Ivison highlighted the civic significance of the programme: “We’re putting PhD researchers into Greater 91ֱ�� colleges to teach alongside experienced staff – starting with engineering, where skills shortages are most acute. This will help colleges with specialist expertise, give our researchers valuable paid teaching experience, and create clearer pathways between further and higher education. This is the kind of collaboration that will contribute to the region’s economic growth and is exactly what a civic university should be doing.”

Professor Callum Kidd, who led the pilot programme, said: “This initiative strengthens the link between Higher Education and Further Education, creating pathways for learners and tackling regional skills gaps. It also offers PhD researchers real-world teaching experience that enhances their career prospects.”

The pilot phase of the programme was launched in 2025 at Wigan & Leigh College, where three postgraduate researchers from the School of Engineering were recruited through the Faculty of Science and Engineering (FSE) Doctoral Academy. The project has been chaired by Professor Callum Kidd (FSE) and jointly developed by a cross-institutional team.‑institutional team

Anna Dawe, Principal of Wigan & Leigh College, added: “We are delighted to build together this partnership with The University of Manchester. Bringing PhD researchers into our colleges enriches students' learning experience and helps address the pressing need for skilled educators in technical subjects. This collaboration is a fantastic example of how Greater 91ֱ��’s education ecosystem can work together to deliver real impact.”

The programme aligns with national and regional priorities to strengthen the civic role of universities while boosting access to specialist expertise across FE colleges.

Following the success of the first phase, the project team is now developing plans to expand the programme across the full Faculty of Science and Engineering, with long term ambitions to extend it university wide. Discussions with additional Further Education colleges in Greater 91ֱ�� are underway, with participating institutions set to be confirmed later this year. A full review of the pilot phase will be completed in February 2026.‑term ambitions to extend it university‑wide. Discussions with additional Further Education colleges in Greater 91ֱ�� are underway, with participating institutions set to be confirmed later this year. A full review of the pilot phase will be completed in February 2026.

For further information please directly contact mags.bradbury@manchester.ac.uk